FUNDING THE "INNOVATION"
While targeting the unmet medical needs of the pharmaceutical industry for the development of safer and faster drugs, innovation is the highest priority at Firalis SA. In products or services, innovation is a key component towards the financial success, in such a rapidly growing worldwide market of biomarkers.
Since its foundation in 2008 by seven associates (pharma managers, pioneering biomarker experts, senior clinicians and key opinion leaders), Firalis successfully closed several rounds of fundraising with > 3 M€ from VC funds, from crowdfunding as well as the founder associates. On top, Firalis Group also received several research prizes and more than 20 M€ of research grant, from many collaborative R&D Projects mostly in the form of subventions from the European Community (IMI, FP7, Eurostars, Horizon2020-twice) as well as from the French institutions such as BPI (Banque Public d'Investissment), ANR (Agence Nationale de Recherche) and the Ministry of Research (Lauréat 2009).
a unique "Value Proposition"
Via its innovative products and a solid IP portfolio incl. several granted patents,
through its clinically qualified biomarkers and in-vitro blood diagnostic tests,
Firalis S.A. is a European leader SME offering an excellent investment opportunity!
Prof. Hüseyin FIRAT, Founding CEO of Firalis S.A.
at the award ceremony of « Entrepreneur of the Year » organized since 22 years by Ernst & Young
and the french journal "Express", where Firalis is awarded as "The Enterprise of Future" (2014).
